Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Alzheimer's benefits in supplements - NIH panel

This article was originally published in The Tan Sheet

Executive Summary

Data do not support the association of dietary supplement intake and drug regimens with reduced risk of Alzheimer's disease, says a National Institutes of Health panel. Following a state-of-the-science conference April 26-28 in Bethesda, Md., the panel said in a 1statement that longer chain omega-3 fatty acids demonstrate some reduced risk of cognitive decline in longitudinal studies and "may provide new insight into the prevention or delay of cognitive decline or Alzheimer's." Other nutritional interventions, including folate, beta-carotene and vitamins B, E and C, show no consistent cognitive benefits, the panel said. Products touting support for brain and memory health products are a growing supplement segment (2"The Tan Sheet" Dec. 21, 2009)

You may also be interested in...



Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply

Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead

Pipeline Watch: Eight Approvals And Five Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel